Company news
Imugene Ltd (ASX:IMU) news
Imugene Ltd news releases on 6ix. Latest, Oct 31, 2022: First patient dosed in VAXINIA intratumoral cohort 2
Press releases — page 3
First patient dosed in VAXINIA intratumoral cohort 2
October 30, 2022
Preclinical trial of ALA iNKT therapy and IMU onCARlytics
September 26, 2022
First patient IV dosed in VAXINIA Phase 1 clinical trial
September 20, 2022
OGTR grants VAXINIA DIR licence allowing trial expansion
September 19, 2022
Prospectus for the issue of institutional placement options
September 16, 2022
IMUGENE ANNOUNCES A$80 MILLION INSTITUTIONAL PLACEMENT
September 12, 2022
Imugene doses first patient in nextHERIZON Phase 2 trial
September 7, 2022
Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA
August 31, 2022
Annual Report and Appendix 4E
August 30, 2022
FIRST COHORT 3 PATIENT DOSED IN CLINICAL TRIAL OF CHECKVACC
August 9, 2022
Imugene Presents New PD1-Vaxx Data at the 2022 WCLC
August 7, 2022
Final HER-Vaxx Phase 2 Trial Overall Survival Results
June 26, 2022
IMUGENE DOSES FIRST PATIENT IN VAXINIA PHASE 1 TRIAL
May 17, 2022
IMU RECEIVES ETHICS APPROVAL TO START HER-VAXX NextHERIZON
May 9, 2022
Clarification Announcement
May 3, 2022
Termination of Supply Agreement
May 2, 2022
Dose Escalation in Phase 1 Clinical Trial of CHECKvacc
March 23, 2022
Clinical Trial of New Cancer Oncolytic Virotherapy Vaxinia
March 22, 2022
Imugene HER-Vaxx Clinical Trial Collaboration with Merck
March 14, 2022
Oncolytic Virotherapy CF33 Patent Granted in Japan
January 30, 2022
PD1-Vaxx Clinical Trial Supply Agreement with Roche
January 28, 2022
HER-Vaxx Immunotherapy Patent Granted in Europe
January 27, 2022
Imugene Receives $6.54 million R&D Tax Incentive
January 6, 2022
South Korea HERVaxx Patent Grant
January 5, 2022
Imugene completes Phase 1a trial of immunotherapy PD1-Vaxx
January 3, 2022
FDA IND APPROVAL FOR THE PHASE 2 CLINICAL TRIAL OF HER-VAXX
December 12, 2021
Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc
December 6, 2021
S&P DJI Announces December 2021 Quarterly Rebalance
December 3, 2021
Clinical Trial Supply Agreement with Merck KGaA and Pfizer
November 15, 2021
Investor Presentation Imugene Eureka Therapeutics
October 31, 2021
FIRST PATIENT DOSED IN PHASE I CLINICAL TRIAL OF CHECKVACC
October 20, 2021
Imugene HER-Vaxx Immunotherapy Patent Granted in Japan
September 21, 2021
S&P DJI Announces September 2021 Quarterly Rebalance
September 3, 2021
Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials
August 31, 2021
Appendix 4E and Full Year Statutory Accounts
August 30, 2021
Phase 1 Clinical Trial Update of Immunotherapy PD1-Vaxx
August 26, 2021
Response to ASX Query
August 23, 2021
Research partnership with Celularity for solid tumors
August 4, 2021
Prospectus for SPP and Placement Options Offer
July 29, 2021
Imugene completes $90 M placement and launches $5 M SPP
July 28, 2021
Appendix 4C - Quarterly Report
July 23, 2021
FDA IND APPROVAL OF NEW ONCOLYTIC VIROTHERAPY CHECKVACC
July 1, 2021
Investor Presentation
May 17, 2021
Prestigious Research Journal Publish HER-Vaxx Phase 1B Data
April 29, 2021
Appendix 4C - quarterly
April 23, 2021
Imugene announces clinical milestone for HER-Vaxx
April 20, 2021
Imugene Oncolytic Virus Presentation at AACR 2021 Meeting
April 11, 2021
Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX
April 6, 2021
S&P DJI Announces March 2021 Quarterly Rebalance
March 12, 2021
Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting
March 10, 2021